期刊文献+

某县HIV感染者基因型耐药检测分析

Analysis of Genotype Drug Resistance in HIV Infectors of One County in Henan Province
下载PDF
导出
摘要 目的了解河南省某县H IV感染者蛋白酶和逆转录酶基因耐药性突变发生的情况。方法采集52例H IV感染者抗凝全血,用扩增/测序(In-House)的方法扩增蛋白酶及逆转录酶基因序列后进行序列测定,提交斯坦福耐药数据库分析耐药性突变。结果52感染者中41例成功扩增并测序,其中43.90%(18/41)发生耐药突变;蛋白酶区耐药突变发生率为36.59%(15/41),均为次要突变,突变类型依次为A71V(5/41),A71T(5/41),A71AT(3/41),A71AV(2/41)和L10I(2/41),第71位碱基突变率为36.59%(15/41);逆转录酶区耐药突变发生率为21.95%(9/41),为主要突变,突变类型主要为K103N(3/41),M41LM(2/41)和T215Y(2/41)。结论河南省确山县H IV感染者已发生较高程度耐药,应加强患者管理及耐药性监测体系,防止耐药毒株的传播。 Objective To investigate HIV infectors'genotype drug resistance in Henan province. Methods 52 plasma samples were separated from the anticoagulatory whole blood, and In - House technique was used to detect the genotype drug resistance. The sequences were submitted to Stanford Drug Resistance Database to analye. Results Sequences of 41 samples were successfully amplified and analyzed. The mutation rate of drug resistance was 43.90% ( 18/41 ). The minor mutation rate of resistance to protease was 36. 59%, including types of A71V (5/41), A71T(5/41 ), A71AT (3/41), A71AV (2/41) and L10I (2/41), The mutation rate of resistance to the 71th base was 36. 59% ( 15/41 ). The major mutation rate of resistance to reverse transcriptase was 21.95%, mainly including types of K103N(3/41) ,M41LM(2/41) and T215Y(2/41 ). Conclusion Most of HIV infectors in Queshan county Henan province were resistant to the currently available antiviral medicine. The system of antiviral management and survilliance should be adjusted to decrease the transmission of drug resistant virus.
出处 《医药论坛杂志》 2008年第9期20-22,共3页 Journal of Medical Forum
关键词 人类免疫缺陷病毒 基因型耐药 序列分析 HIV Genotype drug resistance Sequence analysis
  • 相关文献

参考文献5

二级参考文献21

  • 1程华,钱序,曹广华,支玉红,高燕宁,姜庆五.血站类型和献血方式对献血员感染HIV的影响[J].中国公共卫生,2004,20(9):1061-1063. 被引量:18
  • 2司雪峰,黄海龙,魏民,关琪,宋艳辉,马鹏飞,全宇,邢辉,邵一鸣.我国HIV-1感染者耐药突变的流行性研究[J].中华实验和临床病毒学杂志,2004,18(4):308-311. 被引量:45
  • 3WANGLan,ZHENGXi-wen,QIANHan-zhu,LüFan,XINGHui.Epidemiologic study on human immunodeficiency virus infection among children in a former paid plasma donating community in China[J].Chinese Medical Journal,2005(9):720-724. 被引量:9
  • 4Li Ts, Tubiana R, Katlama C, et al. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet, 1998,351 : 1682-1686.
  • 5Moroni M. Genotypic resistance tests for the management of patients with viro-immunological discordant response to highly active antiretroviral therapy. Scand J Infect Dis Suppl, 2003,106 : 85-87.
  • 6Puro V. Genotypic resistance tests for the management of postexposure prophylaxis. Seand J Infect Dis Suppl, 2003,106 : 93-98.
  • 7Shader RW, Jung DR, Betts BJ, et al. HIV reverse transcriptase and protease sequence database. Nucleic Acids Res, 2000,28 : 346-348.
  • 8Sharer RW, Smeaton LM, Robbins GK, et al. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med, 2003,349:2304-2315.
  • 9Heungsup Sung, Brian TF, In GB, et al. Phylogenetic analysis of reverse transcriptase in antiretroviral drug-naive Korean HIV type 1 patients.AIDS Res and Human Retroviruses, 2001,17 : 1549-1554.
  • 10Little SJ. Transmission and prevalence of HIV resistance among treatment-naive subjects. Antiviral Therapy, 2000,5:33-40.

共引文献51

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部